I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box AF, Assistant Commissioner for Patents, Washington, D.C. 20231 On Peccentage 21, 2000

By:

PECEIVED (4)

OIP E 30 27 2000 24 30 2

Attorney Docket No.: 20093-000120US

## IN THE LIMITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GERALD P. MURPHY et al.

Application No.: 09/016,737

Filed: January 30, 1998

For: ISOLATION AND/OR

PRESERVATION OF DENDRITIC CELLS FOR PROSTATE CANCER

**IMMUNOTHERAPY** 

Examiner:

M. Davis

Art Unit:

1642

AMENDMENT UNDER 37 CFR 1.116

Box AF

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Final Office Action mailed June 21, 2000, please amend this application as follows:

## IN THE CLAIMS:

Please amend the claims as follows:

- 23. (Thrice Amended) A composition[,] comprising [: isolated] an increased number of human dendritic cells [which have been exposed, in vitro,] competent and enabled to activate T cells to a prostate antigen[, wherein said human dendritic cells take up and present said antigen] as compared to those directly isolated from peripheral blood.
- 28. (Twice Amended) The composition according to claim 23, in which the dendritic cells[, following exposure *in vitro* to the prostate tissue antigen, wherein said human

Lars and

13 not enter

1 2

1

2

3

4